Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations will highlight the potential of RNAi therapeutics to transform the treatment of cardiovascular diseas
Related Questions
How will the new hypertension and ATTR data presented at ESC 2025 affect Alnylam's upcoming earnings forecasts?
What is the expected market size for RNAi therapeutics in cardiovascular disease and how might this influence Alnylam's valuation?
When are regulatory filings (e.g., FDA or EMA) anticipated for the hypertension program based on the new data?
What are the projected timelines for potential product approvals and commercial launch in major markets?
How does the progress of Alnylam's RNAi programs compare to competitor pipelines in the same therapeutic area?
Will the ESC 2025 presentations trigger any changes in analyst coverage or target price revisions for ALNY?
What potential partnership or licensing opportunities could arise from the new data, and how might they impact the stock?
Are there any disclosed safety or efficacy concerns in the new data that could affect investor sentiment?
How might the new data influence Alnylam's cash burn rate and future financing needs?
What is the anticipated impact of the new data on Alnylam's long‑term revenue growth and profitability outlook?